IVVDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Invivyd, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.61−0.01 (-1.39%)
Close on Oct 19, 2026
- Market cap
- $195.47M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2020 to 2025
Operating margin
-104.0%
Net margin
-98.2%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +110.5% | – | – | – |
Returns and balance sheet
6 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2020 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -34.0% | |
| Return on assets | – | – | -25.8% | |
| Current ratio | 8.98 | 8.98 | 7.24 | |
| Capex to revenue | – | – | 0.3% | |
| Diluted shares | – | – | 172M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Invivyd generated $806.51M from operations and spent $2.70M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$806.51M
Used
$2.70M
Capital expenditure$2.70M100%Dividends$00%Share buybacks$5.00K0%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-98.2%
×Asset turnover0.26×
×Equity multiplier1.31×
=Return on equity, FY2025-34.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -98.2% | 0.26× | 1.31× | -34.0% |
| FY2024 | -669.4% | 0.14× | 1.46× | -138.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$52.49M
- Cash generatingOperating cash flow above zero-$58.14M
- Return on assets improvedROA up on the prior year-74.1% → -40.5%
- Earnings backed by cashOperating cash flow above net income-$58.14M vs -$52.49M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.62 → 7.24
- No dilutionShare count did not rise119M → 172M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.11 → 0.41